slides · global inventory
Chart
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 78,138
Current window 51,361-51,390
Pages 2,605
Rows per page 30
Component
51,361-51,390 of 78,138
45
The slide uses a bar chart to visualize payment data from CMS OpenPayments to support a narrative of questionable marketing practices.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller Beat · The Struggle1 hit
54
The slide uses a bar chart to compare reporting rates per million daily doses, with specific focus on drugs withdrawn from the market due to cardiac safety concerns.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller Beat · The VictoryLoop · The Reveal1 hit
71
The slide uses a combination of chemical structure diagrams, a tabular summary of clinical trial failures, and a pie chart showing the distribution of indications for failed trials.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
132
The slide highlights a specific discrepancy in an FDA review document (page 32) where the graph title claims 'steady state Cmax' but the underlying data is from a single dose.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
136
Includes a linear regression equation Y=14.62*X+53.34 and a scatter plot with error bars.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
146
The slide uses a 'red flag' narrative to challenge the integrity of clinical trial data reporting.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
147
The slide uses direct excerpts from FDA documents and product labels to highlight a contradiction in clinical trial methodology.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
174
The slide argues that reporting lags or manipulation by Harmony Biosciences obscures the true number of adverse events.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
178
The slide highlights a potential discrepancy between official FDA reporting and actual event timing, suggesting either database lag or manufacturer reporting delays.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
179
The slide uses a 'back-of-the-envelope' calculation to argue that reported adverse events are undercounted.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
212
The slide uses a pie chart to highlight that 38% of study participants were in Russia, suggesting a lack of geographic diversity and potential data manipulation.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
221
The slide uses clinical trial data to undermine the efficacy claims of a drug by highlighting the placebo response.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
223
The author argues that the discrepancy hides a trend reversal that would undermine the trial's efficacy claims.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
233
The slide uses a combination of a pie chart and two tables to substantiate claims of trial design flaws.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
236
The slide uses a pie chart to visualize the geographic concentration of trial participants, specifically pointing out the high percentage in Russia to support a claim of data manipulation.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
298
The slide uses a 'fraud-exposure' approach by highlighting circular citations and methodological weaknesses in the foundational research.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
310
The slide uses a specific scientific paper (Lin et al., 2007) to argue that the drug's mechanism is scientifically implausible based on the provided data.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
313
Includes a quote from a pharmacology consultant comparing pitolisant to antihistamines.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
116
The slide uses a bar chart to expose the unreliability of the quantum computer's output.IonQ Inc. (IONQ) · Scorpion Capital
Activist deck Short seller Loop · Iceberg1 hit
119
The slide uses a grouped bar chart to highlight performance inconsistency across five separate runs.IonQ Inc. (IONQ) · Scorpion Capital
Activist deck Short seller Loop · Iceberg1 hit
122
The slide uses a direct quote from an internal paper to contradict the company's public narrative on scalability.IonQ Inc. (IONQ) · Scorpion Capital
Activist deck Short seller 1 hit
141
The slide uses a screenshot of an investor presentation to contrast public claims with the company's own internal forecasts.IonQ Inc. (IONQ) · Scorpion Capital
Activist deck Short seller Beat · The Conclusion that IonQ's Claims are Exaggerated1 hit
10
The slide highlights a discrepancy between market cap rank (64th in Japan) and trading volume (top 10 globally), comparing it to tech giants and semiconductor peers.Lasertec Corporation (6920) · Scorpion Capital
Activist deck Short seller Beat · Allegations of accounting irregularitiesLoop · Aha Moment1 hit
65
The slide argues that revenue growth is being driven by the drawdown of deferred revenue rather than new business, supported by a line chart and a data table.Lasertec Corporation (6920) · Scorpion Capital
Activist deck Short seller Loop · The Reveal1 hit
66
会計不正のメカニズム（棚卸資産の過大計上と売上原価の過少計上）を説明し、それを裏付けるための時系列チャートを提示。Lasertec Corporation (6920) · Scorpion Capital
Activist deck Short seller Loop · The Reveal1 hit
80
レーザーテック（赤）が他社（黒・グレー・青）と比較して突出していることを強調する比較チャート。Lasertec Corporation (6920) · Scorpion Capital
Activist deck Short seller Loop · The Reveal1 hit
84
The slide highlights a discrepancy in financial reporting practices between Lasertec and its peers.Lasertec Corporation (6920) · Scorpion Capital
Activist deck Short seller 1 hit
86
The slide uses a combination of a bar chart showing inventory/sales ratio and a screenshot of the official press release regarding the auditor change to build a case for potential accounting irregularities.Lasertec Corporation (6920) · Scorpion Capital
Activist deck Short seller 1 hit
90
The slide argues that the unexplained volatility in gross margin is a sign of corporate malfeasance.Lasertec Corporation (6920) · Scorpion Capital
Activist deck Short seller 1 hit
91
The slide uses a transcript excerpt to expose the company's evasiveness regarding the profitability of specific product lines.Lasertec Corporation (6920) · Scorpion Capital
Activist deck Short seller 1 hit